Compare RSVR & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RSVR | NGNE |
|---|---|---|
| Founded | 2007 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 681.9M | 744.9M |
| IPO Year | 2020 | 2014 |
| Metric | RSVR | NGNE |
|---|---|---|
| Price | $10.10 | $22.27 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | $13.00 | ★ $77.63 |
| AVG Volume (30 Days) | 53.1K | ★ 242.2K |
| Earning Date | 11-04-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 8.33 | 0.93 |
| EPS | ★ 0.07 | N/A |
| Revenue | ★ $175,664,491.00 | N/A |
| Revenue This Year | $8.25 | N/A |
| Revenue Next Year | $5.49 | N/A |
| P/E Ratio | $145.43 | ★ N/A |
| Revenue Growth | ★ 10.69 | N/A |
| 52 Week Low | $7.15 | $15.93 |
| 52 Week High | $13.39 | $43.66 |
| Indicator | RSVR | NGNE |
|---|---|---|
| Relative Strength Index (RSI) | 54.03 | 36.47 |
| Support Level | $9.98 | $21.05 |
| Resistance Level | $10.22 | $23.35 |
| Average True Range (ATR) | 0.38 | 1.80 |
| MACD | -0.02 | -0.21 |
| Stochastic Oscillator | 33.82 | 3.13 |
Reservoir Media Inc is an independent music company. The company operates a music publishing business, a recorded music business, a management business, and a rights management entity in the Middle East. The company's segments include Music Publishing and Recorded Music. It generates the maximum of its revenue from the U.S. Music Publishing segment engaged in the acquisition of interests in music catalogs to earn royalties and signing songwriters to agreements of future delivery of songs. The Recorded Music segment involve the acquisition of sound recording catalogs and the discovery and development of recording artists and the marketing, distribution, sale and licensing of the music catalog.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.